Financing round-up: ImmunOs Therapeutics, Esaal, LUCA Science, NuProbe Global, Minoryx

Spain: Minoryx, a clinical stage biotech company, has raised €51m (US$53.6m) to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy. The financing includes Series C equity financing and complementary bank debt. The Series C round was co-led by Columbus Venture Partners and Caixa Capital Risc, and supported by CDTI Innvierte, Fund+,…

You must be a HMI Subscriber to view this content.

Subscribe Now »